CTAS vs SPRB · P/E 51, rev $10.34B vs rev $4.9M
Cintas Corporation (CTAS) versus Spruce Biosciences Inc (SPRB) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Spruce Biosciences Inc (SPRB) is a biotechnology company listed on US.
Latest reported CTAS revenue for 2025-05-31 was $10.34B. Net income was $1.81B. Revenue was up 7.7% from 2024-05-31 to 2025-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported SPRB revenue for 2024-12-31 was $4.9M. Net income was -$53.0M. Revenue was down 51.3% from 2023-12-31 to 2024-12-31. SPRB currently screens at market cap $3.0M.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. SPRB currently screens at market cap $3.0M.
Not investment advice. Open the CTAS and SPRB stock pages for the full models.
Not investment advice.